Apixaban for Extended Anticoagulation (APIDULCIS)

Phase 4

Terminated

• Conditions: Venous Thromboembolism; Anticoagulants
• Interventions: Drug: Apixaban

• Registration Number: NCT03678506
• Lead Sponsor: Arianna Anticoagulazione Foundation

Brief Summary

The study aims at optimizing the long-term and extended management of patients with a first episode of venous thromboembolism (proximal deep vein thrombosis with or without pulmonary embolism) (VTE). Patients at high risk of recurrence (with altered D-dimer test), who had received anticoagulation (whatever the drug used) for 12-15 months after the first episode of thrombosis, will be treated with Apixaban 2,5 mg x 2 for 18 months as extended treatment. Patients at low risk, with normal D-dimer test, will stop anticoagulation definitely.

Detailed Description

This prospective cohort study aims to assess the efficacy and safety of a management procedure to decide on giving or not an extended anticoagulation (administering apixaban 2 2.5 mg twice daily ) to outpatients with a single episode of proximal deep vein thrombosis of the lower limbs and/or pulmonary embolism who had received 12-15 months of anticoagulation (whatever the anticoagulant drug used). The study seeks to assess whether a management procedure involving D-dimer testing assessment can identify a subset of subjects at low risk of recurrence in whom an extended anticoagulation can be safely avoided.

Study Timeline

• Study Start: 2018-08-16
• Study First Submitted: 2018-09-08
• Study First Submitted QC: 2018-09-18
• Study First Posted: 2018-09-19
• Primary Completion: 2021-09-01
• Study Completion: 2023-01-31
• Status Verified: 2023-02
• Last Update Submitted: 2023-02-22
• Last Update Posted: 2023-02-24

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 800

Inclusion Criteria

• First unprovoked Venous Thromboembolic Event
• Venous Thromboembolic events associated with one or more risk factors that are no longer present
• Age older than 18 or younger than 75 years
• Capacity to give written informed consent

Exclusion Criteria

• A) Exclusion criteria regarding the index event

• Events usually associated with low risk of recurrence

• Deep vein thrombosis/ Pulmonary embolism occurred within 3 months from major surgery or major trauma

• Isolated Distal deep vein thrombosis (thrombosis of calf veins)

• Events associated with a very high risk of recurrence or occurrence of life-threatening recurrent events

  • Pulmonary Embolism episode with shock or life-threatening
  • Isolated pulmonary embolism with a systolic pulmonary artery pressure > 60 mmHg at presentation
  • Deep vein thrombosis/ Pulmonary embolism associated with active cancer, antiphospholipid syndrome or long-standing medical illnesses
  • More than one idiopathic event

• Index venous thromboembolic event in different sites than deep veins of the lower limbs or pulmonary arteries

B) Exclusion criteria present at the moment of patients' screening:

• Age younger than 18 or older than 75 years

• More documented unprovoked venous thromboembolic episodes

• Pregnancy or puerperium

• Severe post-thrombotic syndrome (≥ 15 points at the Villalta score)

• Solid neoplasia or blood disease in active phase or requiring chemotherapy/radiotherapy

• All the clinical conditions requiring prolonged treatment with Low Molecular Weight Heparin

• Presence of overt, active chronic diseases (i.e. inflammatory bowel disease)

• Known serious thrombophilic alterations:

  • deficiencies of natural anticoagulants (Antithrombin, Protein C, Protein S)
  • homozygosity for Factor V Leiden or Factor II G20210A mutations
  • double heterozygosity

• Presence of antiphospholipid syndrome

• Presence of vein cava filter

• Concomitant conditions (such as atrial fibrillation) requiring indefinite anticoagulation

• Severe cardio-respiratory insufficiency (NYHA 3 or 4)

• Any absolute contraindications to anticoagulation treatment

• Any other contraindications to Apixaban as per local SmPC

• Life expectancy shorter than 1 year

• Refuse interruption of anticoagulation to perform serial D-dimer assessment

• Geographically inaccessible location

• Inability or refusal to give consent

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Positive D-Dimer	Apixaban	At the first positive D-dimer results (during anticoagulation or after its temporary withdrawal) the patients are invited to assume Eliquis (apixaban) 2.5 mg twice daily, and continue this therapy for the following 18 months.

Primary Outcome Measures

Name	Time	Method
Number and rate of patients with confirmed recurrent VTE and VTE-related death (efficacy).	From date of enrollment until the date of first documented event assessed up to 18 months	The occurrence of proximal deep vein thrombosis with or without pulmonary embolism (new or recurrent episode) wil be recorded in all patients
Number and rate of major Bleeding events (defined according to International Society on Thrombosis and Haemostasis guidelines (safety)	From date of enrollment until the date of first documented event assessed up to18 months	Fatal bleeding; intracranial; intraspinal; intraocular; pericardial; intra-articular; intramuscular with compartment syndrome; retroperitoneal,; acute clinically overt bleeding will be recorded in all patients

Secondary Outcome Measures

Name	Time	Method
Number and rate of non major bleeding complications	From date of enrollment until the date of first documented event assessed up to18 months	In all patients will be recorded any sign or symptom of hemorrhage that does not fit the criteria for the definition of major bleeding but does meet at least one of the following criteria: 1)requiring medical intervention by a healthcare professional; 2) leading to hospitalization or increased level of care;3) prompting a face to face evaluation
Number of and rate of thromboembolic events	From date of enrollment until the date of first documented event assessed up to 18 months	Transient ischemic attack (TIA), Stroke, Myocardial infarction will be recorded in all patients
Presence of severe post-thrombotic syndrome according to Villalta Score	18 months	Patient with deep vein thrombosis as index event will be evaluated, at the and of follow-up, applying Villalta score, commonly used to diagnose post-thrombotic syndrome in the subacute phase of thrombosis. The presence of venous ulcer of the leg or a score \> of 15 points indicate the occurrence of severe post-thrombotic syndrome. The maximum score is 33. The score from 5 to 9 points indicate mild post-thrombotic syndrome and from 10 to 15 points indicate moderate post-thrombotic syndrome
Number and rate of dead patients (overall mortality)	From date of enrollment until the date of first documented event assessed up to 18 months	VTE-related death; cardiovascular related-death; bleeding-related death; death for: cancer, infectious disease and unknown cause; sudden death will be recorded in all patients

Trial Locations

Locations (1)

Daniela Poli; 🇮🇹 Firenze, Italy